Literature DB >> 32089164

The G protein coupled receptor CCR5 in cancer.

Chandan Upadhyaya1, Xuanmao Jiao2, Anthony Ashton3, Kishan Patel1, Andrew V Kossenkov4, Richard G Pestell5.   

Abstract

The G coupled protein receptor CC chemokine receptor type 5 (CCR5) has the unusual characteristic in humans of being a developmentally non-essential gene that participates in several pathological processes including infection with HIV (Dean et al., 1996; Gupta et al., 2019; Samson et al., 1996), progression of stroke (Joy et al., 2019), osteoporosis (Xie et al., 2019) and the metastasis of cancer (Jiao et al., 2018; Velasco-Velazquez et al., 2012, 2014) (Reviewed in: Jiao, Nawab, et al., 2019; Jiao, Wang, & Pestell, 2019). The importance of CCR5 in HIV led to recent genetic engineering of humans to recreate a non-functional CCR5 gene. Thus, although the application of gene-editing tools, to manipulate human embryos is prohibited in the United States, and China. at the Second International Summit on Human Genome Editing in Hong Kong (http://www.nationalacademies.org/), it was claimed that CRISPR-Cas9 systems had been used to edit the CCR5 gene in twin baby girls. The importance of CCR5 in stroke has led to clinical trials using maraviroc (NCT03172026). The key function of CCR5 in cancer metastasis and homing (Jiao et al., 2018; Jiao, Nawab, et al., 2019; Velasco-Velazquez et al., 2012, 2014) has led to three active clinical trials for metastatic cancer using CCR5 antagonists (Jiao, Nawab, et al., 2019; Jiao, Wang, & Pestell, 2019). Thus, it was surprising to find that the all-cause mortality rate in individuals who are homozygous for the CCR5△32 allele in the United Kingdom normal population was increased >20% increase, with an almost 2 year reduction overall lifespan (Wei & Nielsen, 2019). The current review herein discusses the distinct functions of CCR5 in human disease and potential avenues for further research.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCR5; Metastasis; Mutation; Signaling

Mesh:

Substances:

Year:  2020        PMID: 32089164      PMCID: PMC7755305          DOI: 10.1016/bs.acr.2019.11.001

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  88 in total

1.  Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro.

Authors:  Yi-Cheng Wu; Yung-Chi Shen; John Wen-Cheng Chang; Jia-Juan Hsieh; Yen Chu; Cheng-Hsu Wang
Journal:  Cytokine       Date:  2018-04-26       Impact factor: 3.861

2.  High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFβ1.

Authors:  Jie Liu; Caihong Wang; Xuhui Ma; Yang Tian; Chunying Wang; Yan Fu; Yongzhang Luo
Journal:  J Pathol       Date:  2019-01-16       Impact factor: 7.996

3.  The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFα and Chemokines.

Authors:  Adit Ben-Baruch
Journal:  Cancer Microenviron       Date:  2011-12-22

4.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

5.  Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer.

Authors:  Hidekazu Sugasawa; Takashi Ichikura; Hironori Tsujimoto; Manabu Kinoshita; Daisaku Morita; Satoshi Ono; Kentaro Chochi; Hitoshi Tsuda; Shuhji Seki; Hidetaka Mochizuki
Journal:  J Surg Oncol       Date:  2008-04-01       Impact factor: 3.454

6.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Authors:  Razvan Cristescu; Robin Mogg; Mark Ayers; Andrew Albright; Erin Murphy; Jennifer Yearley; Xinwei Sher; Xiao Qiao Liu; Hongchao Lu; Michael Nebozhyn; Chunsheng Zhang; Jared K Lunceford; Andrew Joe; Jonathan Cheng; Andrea L Webber; Nageatte Ibrahim; Elizabeth R Plimack; Patrick A Ott; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan; Joanne E Tomassini; Andrey Loboda; David Kaufman
Journal:  Science       Date:  2018-10-12       Impact factor: 47.728

7.  HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.

Authors:  Ian H Gabriel; Eduardo Olavarria; Ravindra K Gupta; Sultan Abdul-Jawad; Laura E McCoy; Hoi Ping Mok; Dimitra Peppa; Maria Salgado; Javier Martinez-Picado; Monique Nijhuis; Annemarie M J Wensing; Helen Lee; Paul Grant; Eleni Nastouli; Jonathan Lambert; Matthew Pace; Fanny Salasc; Christopher Monit; Andrew J Innes; Luke Muir; Laura Waters; John Frater; Andrew M L Lever; Simon G Edwards
Journal:  Nature       Date:  2019-03-05       Impact factor: 49.962

8.  CCR5 is a receptor for Staphylococcus aureus leukotoxin ED.

Authors:  Francis Alonzo; Lina Kozhaya; Stephen A Rawlings; Tamara Reyes-Robles; Ashley L DuMont; David G Myszka; Nathaniel R Landau; Derya Unutmaz; Victor J Torres
Journal:  Nature       Date:  2012-12-12       Impact factor: 49.962

9.  CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.

Authors:  Mary T Joy; Einor Ben Assayag; Dalia Shabashov-Stone; Sigal Liraz-Zaltsman; Jose Mazzitelli; Marcela Arenas; Nora Abduljawad; Efrat Kliper; Amos D Korczyn; Nikita S Thareja; Efrat L Kesner; Miou Zhou; Shan Huang; Tawnie K Silva; Noomi Katz; Natan M Bornstein; Alcino J Silva; Esther Shohami; S Thomas Carmichael
Journal:  Cell       Date:  2019-02-21       Impact factor: 66.850

10.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Authors:  Gerd Fätkenheuer; Mark Nelson; Adriano Lazzarin; Irina Konourina; Andy I M Hoepelman; Harry Lampiris; Bernard Hirschel; Pablo Tebas; François Raffi; Benoit Trottier; Nicholaos Bellos; Michael Saag; David A Cooper; Mike Westby; Margaret Tawadrous; John F Sullivan; Caroline Ridgway; Michael W Dunne; Steve Felstead; Howard Mayer; Elna van der Ryst
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 176.079

View more
  2 in total

1.  Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.

Authors:  Xuanmao Jiao; Min Wang; Zhao Zhang; Zhiping Li; Dong Ni; Anthony W Ashton; Hsin-Yao Tang; David W Speicher; Richard G Pestell
Journal:  Breast Cancer Res       Date:  2021-01-23       Impact factor: 6.466

Review 2.  Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials.

Authors:  Shuhang Wang; Yuqi Yang; Peiwen Ma; Huiyao Huang; Qiyu Tang; Huilei Miao; Yuan Fang; Ning Jiang; Yandong Li; Qi Zhu; Wei Tao; Yan Zha; Ning Li
Journal:  Mol Ther Oncolytics       Date:  2022-02-22       Impact factor: 7.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.